AURORA CANNABIS INC (ACB.CA) Fundamental Analysis & Valuation

TSX:ACBCA05156X8504

Current stock price

4.67 CAD
-0.12 (-2.51%)
Last:

This ACB.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ACB.CA Profitability Analysis

1.1 Basic Checks

  • In the past year ACB has reported negative net income.
  • In the past year ACB has reported a negative cash flow from operations.
  • In the past 5 years ACB reported 4 times negative net income.
  • In the past 5 years ACB reported 4 times negative operating cash flow.
ACB.CA Yearly Net Income VS EBIT VS OCF VS FCFACB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1B -2B -3B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -11.45%, ACB is in line with its industry, outperforming 48.39% of the companies in the same industry.
  • ACB has a Return On Equity (-16.55%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -11.45%
ROE -16.55%
ROIC N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ACB.CA Yearly ROA, ROE, ROICACB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200 -250

1.3 Margins

  • ACB's Gross Margin of 1.35% is on the low side compared to the rest of the industry. ACB is outperformed by 83.87% of its industry peers.
  • ACB's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ACB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
ACB.CA Yearly Profit, Operating, Gross MarginsACB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

4

2. ACB.CA Health Analysis

2.1 Basic Checks

  • ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ACB has been increased compared to 1 year ago.
  • Compared to 5 years ago, ACB has less shares outstanding
  • ACB has a better debt/assets ratio than last year.
ACB.CA Yearly Shares OutstandingACB.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ACB.CA Yearly Total Debt VS Total AssetsACB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • ACB has an Altman-Z score of -10.46. This is a bad value and indicates that ACB is not financially healthy and even has some risk of bankruptcy.
  • ACB's Altman-Z score of -10.46 is on the low side compared to the rest of the industry. ACB is outperformed by 83.87% of its industry peers.
  • ACB has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.06, ACB is doing good in the industry, outperforming 70.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -10.46
ROIC/WACCN/A
WACC8.82%
ACB.CA Yearly LT Debt VS Equity VS FCFACB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

  • ACB has a Current Ratio of 3.06. This indicates that ACB is financially healthy and has no problem in meeting its short term obligations.
  • ACB has a better Current ratio (3.06) than 77.42% of its industry peers.
  • ACB has a Quick Ratio of 1.48. This is a normal value and indicates that ACB is financially healthy and should not expect problems in meeting its short term obligations.
  • ACB has a Quick ratio of 1.48. This is in the better half of the industry: ACB outperforms 67.74% of its industry peers.
Industry RankSector Rank
Current Ratio 3.06
Quick Ratio 1.48
ACB.CA Yearly Current Assets VS Current LiabilitesACB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

3

3. ACB.CA Growth Analysis

3.1 Past

  • The earnings per share for ACB have decreased strongly by -502.65% in the last year.
  • Looking at the last year, ACB shows a quite strong growth in Revenue. The Revenue has grown by 16.54% in the last year.
  • The Revenue has been growing slightly by 6.94% on average over the past years.
EPS 1Y (TTM)-502.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.83%
Revenue 1Y (TTM)16.54%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%6.79%

3.2 Future

  • ACB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.58% yearly.
  • The Revenue is expected to grow by 1.94% on average over the next years.
EPS Next Y-2493.7%
EPS Next 2Y27.12%
EPS Next 3Y76.74%
EPS Next 5Y103.58%
Revenue Next Year5.63%
Revenue Next 2Y-0.69%
Revenue Next 3Y5.96%
Revenue Next 5Y1.94%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ACB.CA Yearly Revenue VS EstimatesACB.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ACB.CA Yearly EPS VS EstimatesACB.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

1

4. ACB.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ACB. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 57.80, the valuation of ACB can be described as expensive.
  • The rest of the industry has a similar Price/Forward Earnings ratio as ACB.
  • The average S&P500 Price/Forward Earnings ratio is at 21.68. ACB is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 57.8
ACB.CA Price Earnings VS Forward Price EarningsACB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACB.CA Per share dataACB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • ACB's earnings are expected to grow with 76.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.12%
EPS Next 3Y76.74%

0

5. ACB.CA Dividend Analysis

5.1 Amount

  • ACB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

ACB.CA Fundamentals: All Metrics, Ratios and Statistics

AURORA CANNABIS INC

TSX:ACB (4/28/2026, 7:00:00 PM)

4.67

-0.12 (-2.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength39.37
Industry Growth47.76
Earnings (Last)02-04
Earnings (Next)06-16
Inst Owners13.03%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap264.84M
Revenue(TTM)373.12M
Net Income(TTM)-88.74M
Analysts74
Price Target7.77 (66.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-336.98%
Min EPS beat(2)-587.94%
Max EPS beat(2)-86.02%
EPS beat(4)0
Avg EPS beat(4)-329.23%
Min EPS beat(4)-587.94%
Max EPS beat(4)-86.02%
EPS beat(8)2
Avg EPS beat(8)402.7%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.71%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.46%
Revenue beat(4)3
Avg Revenue beat(4)0.88%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)2.46%
Revenue beat(8)6
Avg Revenue beat(8)4.2%
Revenue beat(12)9
Avg Revenue beat(12)4.15%
Revenue beat(16)9
Avg Revenue beat(16)1.91%
PT rev (1m)8.47%
PT rev (3m)-2.31%
EPS NQ rev (1m)-70%
EPS NQ rev (3m)-355.03%
EPS NY rev (1m)-2.38%
EPS NY rev (3m)-62.33%
Revenue NQ rev (1m)-3.12%
Revenue NQ rev (3m)-20.65%
Revenue NY rev (1m)-0.54%
Revenue NY rev (3m)-4.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 57.8
P/S 0.71
P/FCF N/A
P/OCF N/A
P/B 0.49
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)0.08
Fwd EY1.73%
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS6.58
BVpS9.46
TBVpS8.38
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -11.45%
ROE -16.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.35%
FCFM N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score3
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.54%
Cap/Sales 5.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.06
Quick Ratio 1.48
Altman-Z -10.46
F-Score3
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-502.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.83%
EPS Next Y-2493.7%
EPS Next 2Y27.12%
EPS Next 3Y76.74%
EPS Next 5Y103.58%
Revenue 1Y (TTM)16.54%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%6.79%
Revenue Next Year5.63%
Revenue Next 2Y-0.69%
Revenue Next 3Y5.96%
Revenue Next 5Y1.94%
EBIT growth 1Y-17.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.2%
EBIT Next 3Y33.11%
EBIT Next 5Y21.95%
FCF growth 1Y63.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.56%
OCF growth 3YN/A
OCF growth 5YN/A

AURORA CANNABIS INC / ACB.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ACB.CA.


What is the valuation status of AURORA CANNABIS INC (ACB.CA) stock?

ChartMill assigns a valuation rating of 1 / 10 to AURORA CANNABIS INC (ACB.CA). This can be considered as Overvalued.


How profitable is AURORA CANNABIS INC (ACB.CA) stock?

AURORA CANNABIS INC (ACB.CA) has a profitability rating of 1 / 10.


Can you provide the financial health for ACB stock?

The financial health rating of AURORA CANNABIS INC (ACB.CA) is 4 / 10.